From: Enhanced immune complex formation in the lungs of patients with dermatomyositis
DM-ILD group | IPF group | P value | |
---|---|---|---|
Number | 18 | 19 | |
Age | 54 (46–63) | 65 (62–67) | 0.001 |
Sex: male | 6 (33%) | 18 (95%) | 0.001 |
RP-ILD or IPF-AE | 9 (50%) | 9 (47%) | |
Tissue collection method | |||
SLB | 11 (61%) | 10 (53%) | |
Transplant | 1 (6%) | 0 (0%) | |
Autopsy | 6 (33%) | 9 (47%) | |
Dx of IIMs | |||
DM | 12 (67%) | – | |
CADM | 6 (33%) | – | |
Histological pattern | |||
DAD | 11 (61%) | 9 (47%) | |
NSIP | 6 (33%) | 0 (0%) | |
UIP | 1 (6%) | 10 (53%) | |
Treatment for autopsy and lung transplant cases | |||
Corticosteroid | 7 (100%) | 8 (89%) | |
Calcineurin inhibitors | 6 (86%) | 2 (22%) | |
Cyclophosphamide | 5 (71%) | 3 (33%) | |
Cause of death in autopsy cases | |||
Respiratory failure (including IPF-AE or RP-ILD) | 6 (100%) | 6 (67%) | |
Lung cancer | 0 (0%) | 3 (33%) |